Metahexamide
 ![]()  | |
| Names | |
|---|---|
|  IUPAC name
 1-(3-amino-4-methylphenyl)sulfonyl-3-cyclohexylurea  | |
| Identifiers | |
|  565-33-3  | |
| 3D model (Jmol) | Interactive image | 
| ChEMBL |  ChEMBL507419  | 
| ChemSpider |  10785  | 
| ECHA InfoCard | 100.008.434 | 
| KEGG |  D07117  | 
| PubChem | 11259 | 
| UNII |  T3U6F5D722  | 
 
  | |
 
  | |
| Properties | |
| C14H21N3O3S | |
| Molar mass | 311.4 g/mol | 
| Pharmacology | |
| A10BB10 (WHO) | |
|   Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).  | |
|   | |
| Infobox references | |
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
References
- ↑ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
 
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
